ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1855

TMEM27 Expression and Clinical Characteristics and Survival in Clear Cell Renal Cell Carcinoma

Session Information

Category: Onco-Nephrology

  • 1500 Onco-Nephrology

Authors

  • Grewal, Rickinder, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
  • Choung, Hae Yoon Grace, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
  • Roberts, Lisa Lembeck, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
  • Beane, Timothy Jason, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
  • Chen, Luojing, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
  • Gilroy, Daniel X., Rochester Institute of Technology, Rochester, New York, United States
  • Le, Thu H., University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
Background

Transmembrane protein 27 (TMEM27/collectrin), a glycoprotein and homolog of angiotensin-converting enzyme 2 (ACE2), is a regulator of renal amino acid uptake in the proximal tubule and may have a protective role in hypertension. Two previous reports have shown that the absence of TMEM27 expression in clear cell renal cell carcinoma (ccRCC) correlates with poorer cancer-related survival. Here we report our findings of TMEM27 expression in ccRCC and clinical outcomes.

Methods

We conducted a retrospective analysis to identify all cases of ccRCC diagnosed between 2010 and 2015 at the University of Rochester Medical Center. The intensity of TMEM27 immunostaining on tumor tissue was semi-quantitatively graded on a scale of 0, 0.5, 1, 1.5, 2, 2.5, and 3 by a single pathologist, and correlated with tumor characteristics and survival.

Results

There were 321 cases of ccRCC. There was evidence of metastasis at time of nephrectomy in 36 (11.2%), and at the latest follow up in 70 (21.8%), and 82 (25.5%) died as of Spring 2021. TMEM27 staining intensity correlated inversely with various tumor characteristics (Table 1). Kaplan-Meier survival analysis showed worse all-cause mortality for tumors without any TMEM27 staining (0) compared to 0.5 or higher, p = 0.02 by log-rank test.

Conclusion

The absence of TMEM27 expression is associated with more aggressive tumor characteristics and poorer all-cause mortality in ccRCC. TMEM27 may be a useful biomarker to assess cancer prognosis. Further studies are needed to better assess if TMEM27 is protective in RCC.

Table 1: Correlation between TMEM27 Staining and Clinical Characteristics
Clinical Characteristicr valuep-value
Tumor size-0.191<0.001
TNM stage (pTx)-0.145<0.01
TNM stage (Nx)-0.152NS
Furhman grade-0.187<0.001
Sarcomatoid rhabdoid present-0.073NS
Large vessel venous invasion-0.113<0.05
Lymphatic invasion-0.072NS
Metastasis at time of nephrectomy-0.126<0.05
Metastasis at follow-up-0.094NS
Composite-0.201<0.001
Composite with death-0.202<0.001

NS: Not Significant, TNM: Tumor, Node, Metastasis